Dingxiao Zhang

List of Publications by Year
in descending order

33 papers	1,346 citations	361413 20 h-index	434195 31 g-index
34 all docs	34 docs citations	34 times ranked	2474 citing authors

#	Article	IF	Citations
1	AÂm6Avalue predictive of prostate cancer stemness, tumor immune landscape and immunotherapy response. NAR Cancer, 2022, 4, zcac010.	3.1	7
2	RBM38 in cancer: role and mechanism. Cellular and Molecular Life Sciences, 2021, 78, 117-128.	5.4	13
3	Genetically engineered oncolytic bacteria as drug delivery systems for targeted cancer theranostics. Acta Biomaterialia, 2021, 124, 72-87.	8.3	29
4	Integrins regulate stemness in solid tumor: an emerging therapeutic target. Journal of Hematology and Oncology, 2021, 14, 177.	17.0	41
5	The spliceosome as a new therapeutic vulnerability in aggressive prostate cancer. Molecular and Cellular Oncology, 2020, 7, 1778420.	0.7	3
6	Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. Nature Communications, 2020, 11, 2089.	12.8	83
7	Quantification of allelic differential expression using a simple Fluorescence primer PCR-RFLP-based method. Scientific Reports, 2019, 9, 6334.	3.3	1
8	The DNA Methylation Status of Wnt and Tgfî² Signals Is a Key Factor on Functional Regulation of Skeletal Muscle Satellite Cell Development. Frontiers in Genetics, 2019, 10, 220.	2.3	15
9	Gene expression profiling of porcine skeletal muscle satellite cells after poly(I:C) stimulation. Gene, 2019, 695, 113-121.	2.2	2
10	Histone 2B-GFP Label-Retaining Prostate Luminal Cells Possess Progenitor Cell Properties and Are Intrinsically Resistant to Castration. Stem Cell Reports, 2018, 10, 228-242.	4.8	36
11	Prostate Luminal Progenitor Cells in Development and Cancer. Trends in Cancer, 2018, 4, 769-783.	7.4	54
12	Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nature Communications, 2018, 9, 3600.	12.8	96
13	â€œSpliceâ€•a way towards neuroendocrine prostate cancer. EBioMedicine, 2018, 35, 12-13.	6.1	4
14	Cancer stem cells: Regulation programs, immunological properties and immunotherapy. Seminars in Cancer Biology, 2018, 52, 94-106.	9.6	100
15	MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nature Communications, 2017, 8, 14270.	12.8	187
16	Developing a Novel Two-Dimensional Culture System to Enrich Human Prostate Luminal Progenitors that Can Function as a Cell of Origin for Prostate Cancer. Stem Cells Translational Medicine, 2017, 6, 748-760.	3.3	19
17	miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells. Oncotarget, 2016, 7, 56628-56642.	1.8	48
18	Deep RNA-Seq analysis reveals unexpected features of human prostate basal epithelial cells. Genomics Data, 2016, 7, 318-320.	1.3	0

#	Article	IF	Citations
19	Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2016, 22, 4505-4516.	7.0	78
20	NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis. Cell Discovery, 2016, 2, 16041.	6.7	41
21	Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer. Nature Communications, 2016, 7, 10798.	12.8	166
22	Transcriptome profiling links the intrinsic properties of human prostate basal cells to prostate cancer aggressiveness. Molecular and Cellular Oncology, 2016, 3, e1168508.	0.7	0
23	Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSAâˆ’/lo castration-resistant cells. Oncotarget, 2016, 7, 14220-14240.	1.8	17
24	Tumor-suppressive functions of 15-Lipoxygenase-2 and RB1CC1 in prostate cancer. Cell Cycle, 2014, 13, 1798-1810.	2.6	22
25	Ndc80 Regulates Meiotic Spindle Organization, Chromosome Alignment, and Cell Cycle Progression in Mouse Oocytes. Microscopy and Microanalysis, 2011, 17, 431-439.	0.4	34
26	Regulation of Maternal Gene Expression by MEK/MAPK and MPF Signaling in Porcine Oocytes During In Vitro Meiotic Maturation. Journal of Reproduction and Development, 2011, 57, 49-56.	1.4	43
27	Arginine and Glutamate-rich 1 (ARGLU1) Interacts with Mediator Subunit 1 (MED1) and Is Required for Estrogen Receptor-mediated Gene Transcription and Breast Cancer Cell Growth. Journal of Biological Chemistry, 2011, 286, 17746-17754.	3.4	55
28	Molecular characterization and polyadenylationâ€regulated expression of cyclin B1 and Cdc2 in porcine oocytes and early parthenotes. Molecular Reproduction and Development, 2010, 77, 38-50.	2.0	24
29	Involvement of ERâ€"calreticulinâ€"Ca²⁺signaling in the regulation of porcine oocyte meiotic maturation and maternal gene expression. Molecular Reproduction and Development, 2010, 77, 462-471.	2.0	26
30	A link between the interleukinâ€6/Stat3 antiâ€apoptotic pathway and microRNAâ€21 in preimplantation mouse embryos. Molecular Reproduction and Development, 2009, 76, 854-862.	2.0	39
31	Involvement of polyadenylation status on maternal gene expression during in vitro maturation of porcine oocytes. Molecular Reproduction and Development, 2009, 76, 881-889.	2.0	19
32	Aberrant epigenetic reprogramming of imprinted microRNA-127 and Rtl1 in cloned mouse embryos. Biochemical and Biophysical Research Communications, 2009, 379, 390-394.	2.1	37
33	Chromosomal localization, spatio-temporal distribution and polymorphism of the porcine tripartite motif-containing 55 <i>(TRIM55) </i>gene. Cytogenetic and Genome Research, 2006, 114, 93B-93B.	1.1	6